Medtronic plc (MDT)
Medtronic (MDT) Up 0.7% Since Last Earnings Report: Can It Continue?
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?
Medtronic: An Undervalued Stock With Durable Competitive Advantages
Medtronic, a global developer and manufacturer of medical devices for chronic diseases, is now a $111 billion (by market cap) healthcare behemoth. Medtronic has increased its dividend for 47 consecutive years, with a 10-year dividend growth rate of 9.8%. Medtronic advanced its revenue from $20.3 billion in FY 2015 to $32.4 billion in FY 2024, a compound annual growth rate of 5.3%.
2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $200
The best dividend stocks have a consistent history of paying and raising dividends in a wide range of economic landscapes. Medtronic is benefiting from its extensive portfolio of medical devices, and profits are growing.
3 Reasons Medtronic's Stock Can Continue Rallying Higher
Medtronic has been consistently growing at around single digits for several quarters. The company has launched around 130 products in the past year.
Medtronic Keeps Capturing High-Growth Markets: Time to Buy MDT Stock?
MDT stock breaking above its 200 and 50-day SMAs can be a piece of good news for investors, signaling an uptrend.
Medtronic Stock: Growth On Rise of the Cardiovascular Machines
Medtronic plc NYSE: MDT is a leading global medical device maker in the medical sector. Its innovative and critical medical device portfolio addresses chronic diseases an aging population suffers.
Billionaire Ray Dalio's Former Hedge Fund Is Buying These 3 Top Dividend Stocks. Should You?
Billionaire Ray Dalio's former hedge fund has recently invested in three top dividend stocks. ExxonMobil, Medtronic, and Microsoft all offer attractive dividend profiles.
Medtronic plc (MDT) 2024 Wells Fargo Healthcare Conference
Medtronic plc (NYSE:MDT ) 2024 Wells Fargo Healthcare Conference September 4, 2024 11:35 AM ET Company Participants Geoff Martha - Chairman & CEO Conference Call Participants Larry Biegelsen - Wells Fargo Larry Biegelsen Good afternoon or good morning, and it's about to be good afternoon and welcome to the 2024 Wells Fargo Healthcare Conference. Thank you for helping make this our largest healthcare conference yet.
Is Medtronic Stock a Buy?
Medtronic hasn't been growing its sales at an impressive clip of late. However, one of the company's segments looks increasingly promising.
This Is Great News for Medtronic, but Is It Time to Buy the Stock?
Medtronic delivered a strong first-quarter earnings report. The company benefits from continued market adoption of several new product launches over the past year.
Medtronic: Is The Company Back?
Medtronic faced challenges, including poor focus, lack of innovation, and COVID-19 impact, leading to share price stagnation since 2018. Despite recent improvements in performance, Medtronic remains undervalued with solid competitive advantages and a promising dividend streak. The company's focus on innovation, strong market position, and dividend growth potential make it a long-term buy for conservative investors.
Diabetes and Neuro Products Ignite Medtronic's Q1 Earnings Rally
Shares of medical device manufacturer Medtronic PLC NYSE: MDT are down about 35% from their highs of roughly three years ago, but promising results from the company's first quarter of fiscal 2025, which ended July 26, could help to drive renewed upward momentum. Specifically, Medtronic's diabetes and neuromodulation products may be poised for breakout growth, and the company's up-and-coming products in various stages of development offer promise as well.
